Recent Advances in Basic and Clinical Nanomedicine - 16/08/11

Doi : 10.1016/j.mcna.2007.05.009

K. John Morrow, PhD ^a, Raj Bawa, MS, PhD ^b,^c,^d,^⁎ , Chiming Wei, MD, PhD, FACC, FAHA, FAAN ^e
^a Newport Biotechnology Consultants, 625 Washington Avenue, Newport, KY 41071, USA
^b Bawa Biotechnology Consulting, LLC, 21005 Starflower Way, Ashburn, VA 20147, USA
^c Rensselaer Polytechnic Institute, 110 8th Street, J Building, Troy, NY 12180, USA
^d Extended Learning Institute—Northern Virginia Community College, Annandale, VA 22003, USA
^e Department of Surgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street/Harvey 606, Baltimore, MD 21205, USA

Corresponding author. Bawa Biotechnology Consulting, LLC, 21005 Starflower Way, Ashburn, VA 20147.

Abstract

Nanomedicine is a global business enterprise. Industry and governments clearly are beginning to envision nanomedicine’s enormous potential. A clear definition of nanotechnology is an issue that requires urgent attention. This problem exists because nanotechnology represents a cluster of technologies, each of which may have different characteristics and applications. Although numerous novel nanomedicine-related applications are under development or nearing commercialization, the process of converting basic research in nanomedicine into commercially viable products will be long and difficult. Although realization of the full potential of nanomedicine may be years or decades away, recent advances in nanotechnology-related drug delivery, diagnosis, and drug development are beginning to change the landscape of medicine. Site-specific targeted drug delivery and personalized medicine are just a few concepts that are on the horizon.

Le texte complet de cet article est disponible en PDF.